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Background: Cardiotoxicity is a major complication of anticancer drugs, including anthracyclines and 5-fluorouracil
(5-FU) and it can have detrimental effects both in patients and workers involved in the preparation of
chemotherapy.
Methods: Specifically, we have assessed the effects of increasing concentrations of 5-FU and doxorubicin (DOXO)
on proliferation of H9c2 rat cardiocytes and HT-29 human colon adenocarcinoma cells by MTT assay. Cells were
treated for 24, 48 and 72 h with different concentrations of the two drugs alone or with 5-FU in combination with
10-4 M of levofolene (LF).
Results: 5-FU induced a time- and dose-dependent growth inhibition in both cell lines. The 50% growth inhibition
(IC:50) was reached at 72 h with concentrations of 4 μM and 400 μM on HT-29 and H9c2, respectively. The addition
of LF to 5-FU enhanced this effect. On the other hand, the IC:50 of DOXO was reached at 72 h with concentrations
of 0.118 μM on H9c2 and of 0.31 μM for HT-29. We have evaluated the cell death mechanism induced by 50%
growth inhibitory concentrations of 5-FU or DOXO in cardiocytes and colon cancer cells. We have found that the
treatment with 400 μM 5-FU induced apoptosis in 32% of H9c2 cells. This effect was increased by the addition of
LF to 5-FU (38% of apoptotic cells). Apoptosis occurred in only about 10% of HT-29 cells treated with either 5-FU or
5-FU and LF in combination. DOXO induced poor effects on apoptosis of both H9c2 and HT-29 cells (5–7%
apoptotic cells, respectively). The apoptosis induced by 5-FU and LF in cardiocytes was paralleled by the activation
of caspases 3, 9 and 7 and by the intracellular increase of O2− levels.
Conclusions: These results suggest that cardiotoxic mechanism of chemotherapy agents are different and this
disclose a new scenario for prevention of this complication.
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Chemotherapy agents have a low therapeutic index thus
affecting also normal cells and not only cancer counter-
parts. On this light, they induce often side effects in can-
cer patients that severely limit their activity. Moreover,
many studies have assessed the risk of workers who han-
dle anti-neoplastic drugs [1-15]. The health hazard for
medical personnel administering these drugs is a major
concern as these drugs are classified as potentially car-
cinogenic, mutagenic or teratogenic [16]. Exposure can* Correspondence: michele.caraglia@unina2.it
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reproduction in any medium, provided the oroccur mainly to hands and sporadically to other body
parts as well. As these drugs directly or indirectly affect
DNA, not only the cancer patients but also the medical
personnel chronically handling these drugs are at a
higher risk for acquiring DNA damage.
Cardiotoxicity is a major complication of anticancer
drugs, including anthracyclines and 5-fluorouracil (5FU)
[17-20]. Anthracyclines are the best studied among the
anticancer drugs with established cardiotoxicity [21,22].
They produce cardiac toxicity accompanied by an in-
crease in myofibrillar disarray that is mediated by the
signaling function of neuregulin 1 [23]. In addition,
anthracyclines induce mitochondrial apoptosis pathways
and free radical production [24,25].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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produce cardiovascular toxicities have also been investi-
gated. 5-FU, a widely used chemotherapeutic, has direct
toxic effects on vascular endothelium that involves endo-
thelial nitric oxide (NO) synthase and leads to coronary
spasms and endothelium-independent vasoconstriction
via protein kinase C [26-32]. Therefore, also for this lat-
ter drug unexpected cardiotoxicity can occur above all in
old patients who have often associated co-morbidities
and can be defined frail patients. Above all in this latter
category of patients, the understanding of the molecular
mechanisms at the basis of the cardiotoxic effects
induced by anti-cancer agents could be useful in order to
determine possible pharmacological strategies in order to
prevent this deleterious side effect. Moreover, the toxic
effects on normal cells (cardiocytes) could differ from
those induced in cancer cells (i.e.: colon cancer cells) and
this could allow the use of cardioprotective agents with-
out affecting the anti-cancer properties of 5-FU. It has
also to be considered that an unexpected high risk of ex-
posure to 5-FU was recently found in a population of
workers of South Italy involved in the manipulation of
cytostatic agents [33]. In the present study, we have eval-
uated the cardiotoxic effects of 5-FU and DOXO on rat
cardiocytes (H9c2) [30] and a human colon adenocarcin-
oma (HT-29) cell line, already reported to be sensitive to
5-FU, for the study of the cell death pathways induced in
cardiac and colon cancer cells.
Materials and methods
Materials
RPMI, DMEM, and FBS were purchased from Flow La-
boratories (Milan, Italy). Tissue culture plasticware was
from Microtech (Naples, Italy). Rabbit antiserum raised
against caspase 9 and monoclonal antibodies (mAb)
raised against caspase 3 and caspase 7 were purchased
from Enzo Life Sciences (Florence, Italy). Hydroethidine
conjugated secondary antibody was purchased from
Sigma-Aldrich (Italy). Mouse antiserum raised against
α−tubulin was purchased by Calbiochem (Merck KGaA,
Darmstadt, Germany). 5-FU, Doxorubicin and were
Levofolene were a gift of Dr. Gaetano Facchini (I.N.T.
‘Pascale’, Naples, Italy).
Cell culture and proliferation
The rat cardiocytes (H9c2) cell line and the human
colon adenocarcinoma (HT-29) cell line obtained from
the American Type Tissue Culture Collection, Rockville,
MD, grow in DMEM and RPMI1640, respectively, sup-
plemented with heat inactivated 20% FBS, 20 mM
HEPES, 100 U/ml penicillin, 100 mg/ml streptomycin,
1% L-glutamine and 1% sodium pyruvate. Both cell lines
were grown in a humidified atmosphere of 95% air/5%
CO2 at 37 °C.Proliferation of H9c2 and HT-29 cell lines was per-
formed in the presence of 5-FU and Doxorubicin
(DOXO) in presence or not of Levofolene (LF), by MTT
assay as previously described [28].
Western blot analysis
H9c2 and HT-29 cell lines were grown for 48 h with or
without DOXO or 5-FU in presence or not of LF at 37°
C. For cell extract preparation, the cells were washed
twice with ice-cold PBS, scraped and centrifuged for
30 min at 4°C in 1 ml of lysis buffer (1% Triton, 0.5% so-
dium deoxycholate, 0.1 NaCl, 1 mM EDTA, pH 7.5,
10 mM Na2HPO4, pH 7.4, 10 mM PMSF, 25 mM benza-
midin, 1 mM leupeptin, 0.025 units/ml aprotinin). Equal
amounts of cell proteins were separated by SDS-PAGE,
electrotransferred to nitrocellulose and reacted with the
different antibodies. Blot were then developed using
enhanced chemiluminescence detection reagents (Super-
Signal West Pico, Pierce) and exposed to x-ray film. All
films were scanned by using Quantity One software
(BioRad laboratories, Hercules, CA).
Flow cytometric analysis of apoptosis
Annexin V-FITC (fluorescein isothiocyanate) was used
in conjunction with a vital dye, Propidium Iodide (PI), to
distinguish apoptotic (Annexin V-FITC positive, PI
negative) from necrotic (Annexin V-FITC positive, pro-
pidium iodide positive) cells. Briefly, cells were incubated
with Annexin-V–FITC (MedSystems Diagnostics, Vi-
enna, Austria) and propidium iodide (Sigma, St. Louis,
MO, USA) in a binding buffer (10 mM Hepes, pH 7.4,
150 mM NaCl, 5 mM KCl, 1 mM MgCl2, 2.5 mM CaCl2)
for 10 min at room temperature, washed and resus-
pended in the same buffer. Analysis of apoptotic cells
was performed by flow cytometry (FACScan, Becton
Dickinson). For each sample, 2 × 104 events were
acquired. Analysis was carried out by triplicate deter-
mination on at least three separate experiments.
Flow cytometric analysis of oxidative stress
The cells were seeded in 6-multiwell plates at the density
of 3 × 105 cells/well. After 24 h incubation at 37 °C the
cells were treated for different time with the IC50s of 5-
FU and DOXO. The oxidative stress was analysed by
Hydroethidine (HE) staining after 48 h of treatment.
Hydroethidine is used as a vital dye in fluorescence
assays that operates as a probe for measurement of O2
−.
The dye enters the cells freely and is dehydrogenated to
fluorescent ethidium bromide by O2
−. Briefly, the cells
were incubated for 1 h at the end of treatment with
20 ng/ml Hydroethidine stock solution (2,5 mg/ml). At
the time of processing the cells were scraped, washed
twice with PBS and the pellet was resuspended in 1 ml
PBS. The dye accumulation was analysed by FACScan
Table 1 IC50s of the different drugs in cardiocytes and
colon cancer cells
Drugs IC50 H9c2 IC50 HT-29
5-FU 400 μM±0.06 4 μM±0.01
5-FU+ 10−4M LF 43 μM±0.01 2 μM±0.009
DOXO 0.12 μM±0.001 0.31 μM±0.002
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CellQuest software. For each sample, 2 × 104 events were
acquired. Analysis was carried out by triplicate deter-
mination on at least three separate experiments.
Statistical analysis
All data are expressed as mean + SD. Statistical analysis
was performed by analysis of variance (ANOVA) with
Neumann-Keul's multiple comparison test or Kolmogorov-
Smirnov where appropriate.
Results
Effects of DOXO and 5-FU on H9c2 and HT-29 cell
proliferation and apoptosis
We studied the effect of increasing concentrations of
DOXO and 5-FU in presence or not of LF on growth in-
hibition of HT-29 and H9c2 cells by MTT assay as
described in “Materials and Methods”. We have found a
dose and time-dependent growth inhibition in both cell
lines. In details, the IC50 (50% inhibitory concentration)
value of 5-FU was 4 μM and 400 μM in HT29 and
H9c2, respectively (Figure 1 and Table 1). Moreover, LF
potentiated growth inhibition induced by 5-FU. In fact,
IC50 of HT-29 and H9c2 cells was 2 μM and 43 μM, re-
spectively. These results suggest, as expected, that the
colon cancer cell line HT29 was more sensitive to 5-FUFigure 1 Effects of DOXO and 5-FU on H9c2 and HT-29 cell proliferat
5-FU alone (A and D) or combined with LF (B and E) or DOXO alone (C an
percentage of untreated cells. Data are reported as mean of three indepen
times and gave always similar results.than H9c2 normal cells (Table 1). Interestingly, these
concentrations of 5-FU can be reached in vivo after the
routinely used ways of administration of this agent in
the clinical practice [34].
On the other hand, H9c2 cells appeared to be more
sensitive to DOXO than HT-29. In fact, the IC50 of
DOXO was 0.12 μM and 0.31 μM on HT-29 and H9c2,
respectively (Figure 1).
Thereafter, we have evaluated the effects of the differ-
ent treatments in inducing apoptosis, assessed by FACS
analysis after double labelling with Annexin V and PI.
We have found that the treatment with DOXO induced
apoptosis in only about 8% of H9c2 cell population
(Figure 2 and Table 2), while the treatment with 5-FU
alone induced apoptosis in about 38% of H9c2 cell popula-
tion compared to 5% of untreated cells as demonstrated
with FACS analysis. Moreover, when the cells were treated
with 5-FU and exposed to LF about 45% apoptosis wasion. Growth inhibition of H9c2 (A-C) and HT-29 (D-F) cells treated with
d F) for 24, 48 and 72 h, evaluated by MTT assay and expressed as a
dent experiments ± SD. The experiments were repeated at least three
Figure 2 Effects of DOXO and 5-FU on H9c2 and HT-29 apoptosis. FACS analysis after double labelling with PI and Annexin V of H9c2 (A–C)
and HT-29 (D–F) cells treated with 5-FU alone (A and D) or combined with LF (B and E) or DOXO alone (C and F). The experiments were
performed at least three times and the results were always similar. Insets, % of positive cells.
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DOXO and 5-FU, respectively in HT-29 cell line (Figure 2
and Table 2). Therefore, DOXO and 5-FU caused antipro-
liferative effects in cardiocytes and tumour cells with differ-
ent mechanisms.
Modulation of intracellular levels of ROS
To evaluate the intracellular levels of ROS, HT-29 and
H9c2 cells were incubated with dihydroethidine followed
by FACS analysis of the oxidative product, ethidium,
which emits red fluorescence. The mean fluorescenceTable 2 Study of apoptosis in H9c2 and HT-29 cell line
72 h H9c2 Necrosis Late apoptosis Alive Early apoptosis
CTR 0.11 1.11 98.4 0.38
5-FU 2.09 32.36* 60.25 5.30
LF 0.19 0.06 99.73 0.02
5-FU+ LF 1.7 37.6 52.9 7.75
DOXO 0.43 6.35 91.69 1.53
72 h HT29 Necrosis Late apoptosis Alive Early apoptosis
CTR 0.16 0.01 99.66 0.17
5-FU 1.84 10.15 80.86 7.15
LF 1.93 0.48 97.21 0.38
5-FU+ LF 0.68 9.39 84.63 5.30
DOXO 0.67 4.8 90.98 3.55
* In bold: significant changes.intensity (MFI) corresponds to ROS levels and to intra-
cellular oxidative stress due to superoxide anion (O2−)
generation induced by their presence.
In H9c2 cells, 5-FU caused an about 1.5-fold increase
of MFI reaching an increase of about 2-fold of MFI with
the addition of LF indicating a potentiation of oxidative
effects (Figure 3 A,B). In the same experimental condi-
tions, we observed an about 3-fold increase of MFI
induced by DOXO treatment. In HT29 cells, LF did not
potentiate the increase of MFI induced by 5-FU alone
that was of about 2-fold while DOXO induced an about
3-fold increase of MFI. Therefore, the oxidative stress
induced by DOXO was more potent than that one
caused by 5-FU in both cancer cells and cardiocytes.
Moreover, LF potentiated the oxidative stress induced by
5-FU only in cardiocytes and not in colon cancer cells.
Effects of the different treatments on caspase activation
In order to characterize the apoptosis induced in these
cell lines we have evaluated if the different treatments
induced the activation of mediators of the execution
phase of apoptosis.
We have evaluated the cleavage and the consequent
activation of both caspase 9 and 3 with western blotting
using specific antibodies that recognize only the intact
forms of the two enzymes. We have found that 5-FU
increased the cleavage of caspase 3 in H9c2 cells and the
latter was potentiated in presence of LF. These effects
Figure 3 Modulation of intracellular levels of ROS. H9c2 and HT-29 were incubated with dihydroethidine and analyzed by flow cytometry as
described in “Materials and Methods”. (A,C) Flow cytometric analysis of H9c2 (A) and HT-29 (C) cells treated with 5-FU alone or combined with LF
or DOXO alone exposed to dihydroethidine used as a probe for measurement of O2
−. (B,D) Representation of the ROS levels expressed as the
percentage of mean fluorescence intensity (MFI) derived by dihydroethidine oxidation of H9c2 (B) and HT-29 (D) cells treated with 5-FU alone or
combined with LF or DOXO alone. The experiments were repeated at least three times and gave always similar results. Bars, SDs.
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sion (activation index). On the other hand, DOXO
increased the cleavage of caspase 3 and 9 after 24 h from
the beginning of treatment but the latter returned to
basal level after 48 h (Figure 4). Moreover, the different
treatments caused no significant changes of the levels of
pro-caspase 3 and 9 in HT29 cell line (Figure 5).
These results were consistent with the data derived
from FACS analysis; in fact, the treatment with 5-FU
and LF induced a stronger apoptotic effect on cardio-
cytes cell line if compared with that one recorded in
colon adenocarcinoma cell line.
Intracellular increase of ROS is responsible for apoptosis
induced by 5-FU in cardiocytes
In order to study the role of the oxidative stress in the
induction of apoptosis by 5-FU in cardiocytes we have
exposed H9c2 to the scavenger agent N-acetyl cysteine
(NAC) and we have evaluated the effects on apoptosis
and intracellular ROS. The addition of NAC alone to
H9c2 cells had no effects on apoptosis and intracellular
ROS (Figure 6A, B respectively). On the other hand, the
addition of NAC to either 5-FU alone or in combination
with LF completely abrogated the effects of both on
apoptosis and increase in the levels of ROS (Figure 6A,B respectively). We have also used H2O2 as positive con-
trol and we have found that the addition of 200 μM
H2O2 to H9c2 cells caused an about 40% apoptosis with
an about 2-fold increase of intracellular ROS and that
these effects were again abrogated by the concomitant
administration of NAC (Figure 6A, B respectively).
These results strongly suggested that apoptosis
induced by 5-FU in cardiocytes is likely due to the in-
crease in intracellular ROS.
Discussion
In this study we have compared the effects induced by
either 5-FU±LF or DOXO on proliferation of both car-
diocytes H9c2 cell line and human colon adenocarcin-
oma HT-29 cells. We have found that the
antiproliferative activity of 5-FU±LF was more pro-
nounced in colon cancer cells than on cardiocytes and
this effect was not surprising since this was on line with
previous data demonstrating the in vitro activity of these
drugs in colon cancer cell lines [35,36]. Thereafter, we
have characterized the mechanism of cell death caused
by the different treatments and we have found that car-
diocytes were more sensitive to apoptosis induced by 5-
FU and LF than colon cancer cells. In other words, the
cytotoxicity recorded in cardiocytes was in the most part
Figure 4 Effects of the different treatments on caspase activation in H9c2 cells. H9c2 cells were treated with 5-FU alone or combined with
LF or DOXO alone for 48 h at the concentrations inhibiting the 50% of the proliferation of the cardiocytes as previously indicated in Table 1.
Thereafter, the expression of caspase 3, 7 and 9 were evaluated after blotting with specific antibodies that recognise both the full and the
cleaved forms of the proteins, as described in "Materials and Methods". Expression of the house-keeping protein α-tubulin, used as loading
control, was also evaluated. The experiments were performed at least three different times and the results were always similar. CTR, untreated
cells; 5-FU, cells treated with 5-FU alone; 5-FU+ LF, cells treated with 5-FU in combination with LF; DOXO, cells treated with DOXO alone.
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mined in colon cancer cells was due to a different mech-
anism (likely necrosis or autophagy or both). These
results are not surprising on the basis of the reported
side effects of 5-FU. In fact, typical side effects of 5-FU
are myelosupression, nausea, vomiting, diarrhea and sto-
matitis [37]. Cardiotoxicity is the other toxicity [36].
Cardiac side effects are ST segment changes, rhythm ab-
normalities, supraventricular and ventricular dysrhyth-
mias [38] and acute myocardial infarction was also
reported in the literature [39]. In fact, cardiocytes have
protective mechanisms that overcome the apoptotic in-
jury caused by several toxic agents that can circulate in
the bloodstream among which cytotoxic drugs as in the
case of cancer patients treated with chemotherapy [40].
Unfortunately, this program is not able to avoid the in-
jury induced by agents with a very high oxidativeFigure 5 Effects of the different treatments on caspase activation in H
LF or DOXO alone for 48 h at the concentrations inhibiting the 50% of the
Table 1. Thereafter, the expression of caspase 3 and 7 were evaluated after
proteins, as described in "Materials and Methods". Expression of the house-
The experiments were performed at least three different times and the res
5-FU alone; 5-FU+ LF, cells treated with 5-FU in combination with LF; DOXpotential as some anti-cancer agents. Moreover, cardio-
cytes are more prone to go towards the apoptotic pro-
gram because, differently from cancer cells, have a poor
amplification of the protective anti-apoptotic pathways.
The latter are essential in order to allow the develop-
ment and spreading of cancer cells into the whole organ-
ism and cancer cells have the opportunity to develop
them during their long natural history [41].
On the other hand, the increase of the intracellular
ROS caused by 5-FU±LF on both H9c2 and HT-29 was
less than that one determined by DOXO and this effect
was likely due to the reported sensitivity of heart to the
oxidative stress induced by DOXO. Several mechanisms
of the intracellular oxidative stress have been reported,
including generation of free radicals and lipid peroxida-
tion of cardiac membranes [3], myocyte damage induced
by cardiac calcium overload [4], formation of DOX-ironT29 cells. HT-29 cells were treated with 5-FU alone or combined with
proliferation of the colon cancer cells as previously indicated in
blotting with specific antibodies that recognise the full form of the
keeping protein α-tubulin, used as loading control, was also evaluated.
ults were always similar. CTR, untreated cells; 5-FU, cells treated with
O, cells treated with DOXO alone.
Figure 6 Effects of the scavenger NAC on both oxidative stress and apoptosis of H9c2cells. A) FACS analysis after double labelling with PI
and FITC-Annexin V of H9c2 cells treated with 5-FU combined with LF or 200 μμ H2O2 or NAC alone or in combination for 48 h. The experiments
were performed at least three times and the results were always similar. The results show the % of apoptotic cells derived from the sum of the
events calculated as late and early apoptotic cells. Bars, SEs. CTR, untreated cells; H2O2, cells treated with 200μM H2O2 alone; NAC, cells treated
with 5 mM NAC alone; NAC+H2O2, cells treated with 5 mM NAC +200μM H2O2; 5-FU+ LF, cells treated with 5-FU in combination with LF; 5-FU
+ LF +NAC, cells treated with 5-FU in combination with LF and 5 mM NAC. B) H9c2 were incubated with dihydroethidine and analyzed by flow
cytometry as described in “Materials and Methods”. Flow cytometric analysis of H9c2 cells treated with 5-FU combined with LF or 200 μM H2O2
or NAC alone or in combination exposed to dihydroethidine used as a probe for measurement of O2
−. Representation of the ROS levels expressed
as the percentage of mean fluorescence intensity (MFI) derived by dihydroethidine oxidation of H9c2 cells. The experiments were repeated at
least three times and gave always similar results. Bars, SDs. CTR, untreated cells; H2O2, cells treated with 200μM H2O2 alone; NAC, cells treated
with 5 mM NAC alone; NAC+H2O2, cells treated with 5 mM NAC +200μM H2O2; 5-FU+ LF, cells treated with 5-FU in combination with LF; 5-FU
+ LF +NAC, cells treated with 5-FU in combination with LF and 5 mM NAC.
Lamberti et al. Journal of Experimental & Clinical Cancer Research 2012, 31:60 Page 7 of 8
http://www.jeccr.com/content/31/1/60complex [5], impaired myocardial adrenergic regulation,
cellular toxicity of anthracycline metabolites [6], and in-
hibition of beta-oxidation of long chain fatty acids with
the consequent depletion of cardiac ATP [7]. The study
of the activation of caspase cascade suggested a
mytochondria-mediated triggering of the apoptotic pro-
gram in cardiocytes that is conceivable with the involve-
ment of oxidative stress. In order to definitively study
the relevance of the increase of intracellular ROS in the
induction of apoptosis induced by 5-FU±LF, we have
treated cardiocytes with the scavenger NAC and we have
studied the effects on the apoptosis occurrence [42]. We
have indeed found that the addition of NAC to the 5-
FU±LF-treated cardiocytes was able to completely
antagonize the apoptosis.
In conclusion, our data suggest that agents such as 5-
FU different from anthracyclines, that are conventionally
related to the induction of cardiotoxic effects, can also
induce cardiocyte damage through the triggering of an
apoptotic program. This detrimental effect could be due
to the induction of the increase of intracellular ROS and
strategies based upon the use of scavengers such as
NAC could be used in order to prevent this effect. The
data obtained in this study will be confirmed in vivo
with a series of experiments already in preparation.
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